Bicalutamide (Tabi (50 mg)) is a non-steroidal anti-androgen, prescribed for prostate cancer. It blocks testosterone action. The information provided on this page is intended to serve as a ...

The antiandrogen bicalutamide is commonly used in combination with medical or surgical castration in men with prostate cancer. With combined androgen blockade, the usual dose of bicalutamide is 50 mg ...

DETROIT Caraco Pharmaceutical Labs has launched bicalutamide tablets on behalf of Sun Pharma. Bicalutamide tablets are an androgen receptor inhibitor indicated for use in combination therapy with a ...

CASODEX 150 mg daily is not approved for use in patients with locally advanced (T3-4, NX, M0) cancer of the prostate. Following discontinuation of all M1 patients, the trials continued with the T3-4, ...

The ongoing Early Prostate Cancer (EPC) programme is investigating the effects of adding bicalutamide 150 mg/day to standard care (radiotherapy, radical prostatectomy or watchful waiting). This study ...

In their recent article in Journal of Clinical Oncology, Penson et al 1 reported results of a phase II randomized study that compared the efficacy of enzalutamide and bicalutamide in patients with ...

A 65-year-old physician had a PSA-only recurrence of prostate cancer, detected after radical prostatectomy. He had been taking gabapentin (300 mg three times a day) for neuropathic pain, which he ...